Læknaneminn - 01.01.2017, Side 22

Ri
trý
nt
ef
ni
21
72. McIntosh D, Kutcher S, Binder C, Levitt
A, Fallu A, Rosenbluth M. Adult ADHD
and comorbid depression: A consensus­
derived diagnostic algorithm for ADHD.
Neuropsychiatric Disease and Treatment
2009;5:137­50.
73. Sobanski E. Psychiatric comorbidity in adults
with attention­deficit/hyperactivity disorder
(ADHD). European Archives of Psychiatry
and Clinical Neuroscience 2006;256:i26­i31.
74. Kupfer DJ, Frank E, Phillips ML.
Major depressive disorder: new clinical,
neurobiological, and treatment perspectives.
Lancet (London, England) 2012;379:1045­55.
75. Cuijpers P, Dekker J, Hollon SD, Andersson
G. Adding psychotherapy to pharmacotherapy
in the treatment of depressive disorders in
adults: a meta­analysis. The Journal of clinical
psychiatry 2009;70:1219­29.
76. Cuijpers P, van Straten A, Warmerdam
L, Andersson G. Psychotherapy versus
the combination of psychotherapy and
pharmacotherapy in the treatment of
depression: a meta­analysis. Depress Anxiety
2009;26:279­88.
77. IsHak WW, Ha K, Kapitanski N, et al. The
impact of psychotherapy, pharmacotherapy,
and their combination on quality of life in
depression. Harvard review of psychiatry
2011;19:277­89.
78. Pampallona S, Bollini P, Tibaldi G, Kupelnick
B, Munizza C. Combined pharmacotherapy
and psychological treatment for depression:
a systematic review. Archives of general
psychiatry 2004;61:714­9.
79. Pagnin D, de Queiroz V, Pini S, Cassano GB.
Efficacy of ECT in depression: a meta­analytic
review. Focus 2008;6:155­62.
80. Efficacy and safety of electroconvulsive therapy
in depressive disorders: a systematic review
and meta­analysis. Lancet (London, England)
2003;361:799­808.
81. Sérlyfjaskrá. at https://www.serlyfjaskra.is/
82. Unipolar major depression in adults: Choosing
initial treatment. 2016. 2017, at https://
www.uptodate.com/contents/unipolar­
major­depression­in­adults­choosing­initial­
treatment?source=see_link#H51.)
83. Gunnell D, Julia Saperia, and Deborah
Ashby. Selective serotonin reuptake inhibitors
(SSRIs) and suicide in adults: meta­analysis of
drug company data from placebo controlled,
randomised controlled trials submitted to the
MHRA’s safety review. BMJ (Clinical research
ed) 2005;330:385.
84. Stahl SM, Pradko JF, Haight BR, Modell JG,
Rockett CB, Learned­Coughlin S. A review
of the neuropharmacology of bupropion, a
dual norepinephrine and dopamine reuptake
inhibitor. Primary Care Companion to The
Journal of Clinical Psychiatry 2004;6:159­66.
85. Demyttenaere K, and Liesbeth Jaspers. Review:
Bupropion and SSRI­induced side effects. .
Journal of Psychopharmacology, 2008;22:792­
804.
86. Andrade C, Sandarsh S, Chethan KB,
Nagesh KS. Serotonin reuptake inhibitor
antidepressants and abnormal bleeding: a
review for clinicians and a reconsideration of
mechanisms. The Journal of clinical psychiatry
2010;71:1565­75.
87. Lunn M, Hughes RA, Wiffen PJ. Duloxetine
for treating painful neuropathy, chronic pain or
fibromyalgia. The Cochrane Library 2014.
88. Jefferson JW. A review of the cardiovascular
effects and toxicity of tricyclic antidepressants.
Psychosomatic Medicine 1975;37:160­79.
89. Philip Cowen PH, Tom Burns. Shorter
Oxford Textbook of Psychiatry. 6 ed: Oxford
University; 2012.
90. Gaster B, Holroyd J. St John’s wort for
depression: a systematic review. Archives of
Internal Medicine 2000;160:152­6.
91. Williams JW, Mulrow CD, Chiquette E, Noël
PH, Aguilar C, Cornell J. A systematic review
of newer pharmacotherapies for depression
in adults: evidence report summary: clinical
guideline, part 2. Annals of internal medicine
2000;132:743­56.
92. Magnús Blöndahl Sighvatsson HK, Engilbert
Sigurðsson, Jón Friðrik Sigurðsson. Gagnsemi
hugrænnar atferlismeðferðar við lyndis­ og
kvíðaröskunum hjá fullorðnum. Læknablaðið
2011;11.
93. Beck AT. Cognitive therapy and the emotional
disorders. New York 1976.
94. Erikssonr EBS, Kristjánsdóttir H, Sigurðsson
JF, Agnarsdóttir A, Sigurðsson E. Áhrif
þunglyndislyfja og róandi lyfja á árangur af
ósértækri hugrænni atferlismeðferð hópa í
heilsugæslu. Læknablaðið 2013.
95. Meðferð þunglyndis og viðbrögð við
sjálfsvígshættu. 2009. 2017, at http://www.
landlaeknir.is/um­embaettid/greinar/grein/
item16405/Medferd­thunglyndis­og­
vidbrogd­vid­sjalfsvigshaettu.)
96. Raflækningar leiðbeiningar fyrir notendur.
2010. at www.landspitali.is/lisalib/getfile.
aspx?itemid=25321.)
97. Grunhaus L, Dannon PN, Schreiber S, et al.
Repetitive transcranial magnetic stimulation is
as effective as electroconvulsive therapy in the
treatment of nondelusional major depressive
disorder: an open study. Biological psychiatry
2000;47:314­24.
98. Burt T, Lisanby SH, Sackeim HA.
Neuropsychiatric applications of
transcranial magnetic stimulation: a
meta analysis. International Journal of
Neuropsychopharmacology 2002;5:73­103.
99. Martin JLR, Barbanoj MJ, Schlaepfer TE,
Thompson E, Pérez V, Kulisevsky J. Repetitive
transcranial magnetic stimulation for the
treatment of depression. The British Journal of
Psychiatry 2003;182:480­91.
100. Loo CK, Mitchell PB. A review of the efficacy
of transcranial magnetic stimulation (TMS)
treatment for depression, and current and
future strategies to optimize efficacy. Journal of
affective disorders 2005;88:255­67.
101. Daban C, Martinez­Aran A, Cruz N, Vieta E.
Safety and efficacy of Vagus Nerve Stimulation
in treatment­resistant depression. A systematic
review. Journal of Affective Disorders
2008;110:1­15.
102. Kennedy SH, Giacobbe P, Rizvi SJ, et al.
Deep brain stimulation for treatment­resistant
depression: follow­up after 3 to 6 years.
American Journal of Psychiatry 2011;168:502­
10.
103. Engilbert Sigurðsson ÞÓ, Magnús
Gottfreðsson. Hver eru viðhorf Íslendinga til
þunglyndislyfja og hvaða þættir ráða mestu um
mótun þeirra? Læknablaðið 2006;62:374­6.
104. Lawlor DA, Hopker SW. The effectiveness
of exercise as an intervention in the
management of depression: systematic review
and meta­regression analysis of randomised
controlled trials. BMJ (Clinical research ed)
2001;322:763.
105. Daley A. Exercise and depression: a review
of reviews. Journal of Clinical Psychology in
Medical Settings 2008;15:140.
106. Solomon DA, Keller MB, Leon AC, et al.
Multiple recurrences of major depressive
disorder. Am J Psychiatry 2000;157:229­33.
107. Okuda A, Suzuki T, Kishi T, et al. Duration
of untreated illness and antidepressant
fluvoxamine response in major depressive
disorder. Psychiatry and clinical neurosciences
2010;64:268­73.
Vörulisti
www.lyfis.is